Answer
Giotrif (afatinib dimaleate) is not recommended for children or adolescents because safety and efficacy have not been established.
Sources for this answer
- Giotrif 20 mg film-coated tabletsBoehringer Ingelheim Limited · emc · SmPC §4.2 Posology and method of administration · Version 1Document updated
Sources checked